A Study of NGM621 in Participants With Geographic Atrophy

Open to people ages 55 years and up

• Male or female (non-pregnant, non-lactating) subjects ≥ 55 years
• Standard luminance BCVA score of 34 letters or better using ETDRS charts at the starting distance of 4 meters (approximately 20/200 Snellen equivalent or better) in study eye
• Clinical diagnosis of GA secondary to AMD:
• Total GA area must be ≥ 2.5 and ≤ 17.5 mm²
• If GA is multifocal, at least one focal lesion must be ≥ 1.25 mm² (0.5 DA), with the overall area of GA ≥ 2.5 and ≤ 17.5 mm²
• Well demarcated GA with no anatomical evidence of current or prior CNV in the study eye

Study Eye

• GA secondary to a condition other than AMD in either eye (e.g., monogenetic macular dystrophies like Stargardt disease, cone rod dystrophy, or toxic maculopathies)
• Any history of or active choroidal neovascularization (CNV)

Both Eyes

• Any history of or active bacterial, viral, fungal, or parasitic infection in either eye in the 3 months prior to randomization